Renova Therapeutics Overview
- Year Founded
-
2009

- Status
-
Private
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$47.6M
- Investors
-
3
Renova Therapeutics General Information
Description
Operator of a bio-pharmaceutical research company designed to create a portfolio of definitive gene and peptide therapies. The company's bio-pharmacy is engaged in the research and development of gene and peptide therapies, single-dose gene therapies, and peptide infusion treatment, enabling medical professionals to treat congestive heart failure (CHF) and type 2 diabetes.
Contact Information
Website
www.renovatherapeutics.comCorporate Office
- 701 Palomar Airport Road
- Suite 300
- Carlsbad, CA 92011
- United States
Corporate Office
- 701 Palomar Airport Road
- Suite 300
- Carlsbad, CA 92011
- United States
Renova Therapeutics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
9. Later Stage VC | 02-Feb-2024 | $47.6M | Completed | Clinical Trials - Phase 2 | ||
8. Grant | 20-Sep-2019 | Completed | Clinical Trials - Phase 2 | |||
7. Later Stage VC (Series D1) | 31-Jan-2017 | Completed | Product Development | |||
6. Later Stage VC (Series D) | 23-Feb-2016 | Completed | Product Development | |||
5. Grant | 01-Jan-2016 | Completed | Clinical Trials - Phase 2 | |||
4. Later Stage VC (Series C) | 30-Sep-2014 | Completed | Pre-Clinical Trials | |||
3. Early Stage VC (Series B) | 25-Feb-2012 | Completed | Product Development | |||
2. Early Stage VC (Series A) | 10-Aug-2009 | $3.05M | $3.05M | Completed | Startup | |
1. Grant | 02-Sep-2011 | $250K | Completed | Startup |
Renova Therapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series D | ||||||||
Series C | ||||||||
Series B | 320,292 | $0.001000 | $1.23 | $24.6 | $24.6 | 1x | $24.6 | 10.46% |
Series A | 305,000 | $0.001000 | $0.5 | $10 | $10 | 1x | $10 | 9.96% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Renova Therapeutics Comparisons
Industry
Financing
Details
Renova Therapeutics Competitors (82)
One of Renova Therapeutics’s 82 competitors is DiaMedica Therapeutics, a Formerly VC-backed company based in Minneapolis, MN.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
DiaMedica Therapeutics | Formerly VC-backed | Minneapolis, MN | ||||
Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
Korro Bio | Formerly VC-backed | Cambridge, MA | ||||
Taysha Gene Therapies | Formerly VC-backed | Dallas, TX | ||||
Cardurion | Venture Capital-Backed | Burlington, MA |
Renova Therapeutics Investors (3)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
National Heart, Lung, and Blood Institute | Government | |||
Biobrit | Venture Capital | Minority | ||
National Institutes of Health | Government |
Renova Therapeutics FAQs
-
When was Renova Therapeutics founded?
Renova Therapeutics was founded in 2009.
-
Where is Renova Therapeutics headquartered?
Renova Therapeutics is headquartered in Carlsbad, CA.
-
What industry is Renova Therapeutics in?
Renova Therapeutics’s primary industry is Biotechnology.
-
Is Renova Therapeutics a private or public company?
Renova Therapeutics is a Private company.
-
What is Renova Therapeutics’s current revenue?
The current revenue for Renova Therapeutics is
. -
How much funding has Renova Therapeutics raised over time?
Renova Therapeutics has raised $78.1M.
-
Who are Renova Therapeutics’s investors?
National Heart, Lung, and Blood Institute, Biobrit, and National Institutes of Health have invested in Renova Therapeutics.
-
Who are Renova Therapeutics’s competitors?
DiaMedica Therapeutics, Alnylam Pharmaceuticals, Korro Bio, Taysha Gene Therapies, and Cardurion are some of the 82 competitors of Renova Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »